Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 26 systematic review(s)/meta-analysis(es). ^[1-27]
• Abrocitinib 200 mg was more effective than the 100 mg dose in achieving Eczema Area and Severity Index (EASI)-75 and EASI-90 responses, with upadacitinib 30 mg showing the highest efficacy. Dupilumab showed lower efficacy compared to abrocitinib 200 mg and upadacitinib 30 mg across EASI-50, EASI-75, and EASI-90.
• Abrocitinib 100 mg and 200 mg doses significantly improved Investigator’s Global Assessment (IGA) scores versus placebo, with abrocitinib 200 mg and upadacitinib 30 mg yielding better IGA success compared to dupilumab.
• Abrocitinib 200 mg significantly reduced pruritus compared to placebo, with both abrocitinib and upadacitinib effective in pediatric patients.
• Abrocitinib and upadacitinib improved Patient-Oriented Eczema Measure (POEM) and Dermatology Life Quality Index (DLQI) scores significantly compared to placebo, with outcomes similar to dupilumab.
• Abrocitinib (100 mg and 200 mg) was associated with higher incidences of nausea, upper respiratory tract infections, gastrointestinal disorders, headache, and dizziness compared to placebo. Upadacitinib was linked to increased cases of acne, nasopharyngitis, and elevated blood creatine phosphokinase levels.
• Janus kinase (JAK) inhibitors (abrocitinib and upadacitinib) were associated with higher risks of herpes zoster compared to placebo and dupilumab, though serious adverse events leading to discontinuation were not significantly increased.
• Higher doses of abrocitinib (200 mg) and upadacitinib (30 mg) resulted in more frequent occurrences of adverse effects, including nausea, gastrointestinal issues, dizziness, and acne.
• There is no population types or subgroups information available in the reviewed documents.